The $20,000 Pause Button: The Brutal Math Behind Alzheimer's Newest Drug

Kisunla is not a cure, and it does not reverse memory loss; it merely slows down the rate of mental decline by roughly 35% over 18 months, which translates to about four to seven months of preserved cognitive function. To get those extra months, a family must manage a gauntlet of monthly IV infusions, at least four brain MRIs to monitor for potentially dangerous brain swelling, and out-of-pocket costs that easily exceed $10,000 a year even with Medicare. For many, the physical stress of constant routine monitoring outweighs the modest cognitive return.

Let's talk numbers because the drug company's list price of $32,000 a year is a polite fiction.

That figure covers only the glass vials of Kisunla itself, which are shipped to an infusion center once a month.

It does not cover the cost of the nurse who inserts the IV, the facility fee for the chair your parent sits in, or the specialized PET scans required to prove they even qualify.

Then come the MRIs.

Kisunla works by clearing amyloid plaques, which can cause the blood vessels in the brain to leak or swell—a condition known as ARIA.

To catch this before it causes a stroke or seizure, Medicare requires at least four brain MRIs during the first year of treatment.

If your parent has standard Medicare without a robust supplemental policy (Medigap), they are on the hook for 20% of all of this under Part B.

That 20% co-insurance on the drug alone is $6,400.

Add the 20% cut for the MRIs, the neurologist visits, and the infusion center fees, and your actual out-of-pocket cost for year one hovers closer to $12,000 to $15,000.

What do you actually get for that $15,000 and eighteen months of sitting in waiting rooms?

In the drug studies, Kisunla slowed mental decline by about 35% compared to a placebo.

In human terms, that means a person on the drug took about seven months longer to reach the next stage of dementia than someone who wasn't.

Think about that timeline.

You are trading monthly doctor visits, regular blood draws, and the anxiety of waiting for MRI results to see if your dad’s brain is bleeding, all to buy roughly half a year of him recognizing his grandkids.

For some families, that half-year is priceless, and they would spend every dime they have to get it.

But for others, that time is eaten up by the friction of the treatment itself.

If your mom hates leaving the house, gets highly agitated during procedures, or panics inside a loud, tight MRI tube, the physical toll of securing those extra six months might actually reduce her quality of life today.

There is one unique aspect of Kisunla that distinguishes it from its predecessor, Leqembi: you can actually stop taking it.

Once PET scans show that the amyloid plaques have been cleared from the brain, treatment stops.

In the studies, about half of the participants were able to stop taking the drug within twelve months, and 72% stopped by eighteen months.

This sounds like great financial news, but it introduces a different kind of planning challenge.

Stopping the drug does not stop the disease; it simply stops the active clearance of plaques.

Eventually, the underlying decline will resume its march, and your family will still face the inevitable transition to more intensive care.

If you spend $15,000 of your dad's liquid savings on Kisunla in year one, that is $15,000 less he has available for home care or a high-quality memory care facility down the road.

When evaluating care facilities, we look closely at their staffing ratios and state inspection histories—metrics we use to calculate the Palmelle Clarity Score on a scale of 0-100.

Unlike paid referral platforms like A Place for Mom or Caring.com, which only show you facilities that pay them commissions, we look at every single licensed option.

Preserving capital to afford a care facility with a high score is often a much safer bet for long-term comfort than spending it all on a drug that offers a temporary pause.

If you need help sorting through these financial trade-offs or finding the right care option, our Help Me Choose service costs $199 and gives you a clear path forward based on your actual budget.